statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Analysts Offer Insights on Healthcare Companies: Centene (CNC), Haleon PLC (GB:HLN) and Ultragenyx Pharmaceutical (RARE)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Centene (CNC Research Report), Haleon PLC (GB:HLN Research Re...

Optimistic Outlook for Ultragenyx Pharmaceutical's GTX-102 Program Amidst Competitive Validation and Strong Market Potential

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on RARE stock, giving a Buy rating yesterday. Joseph Schwartz has give...

Ultragenyx Posts New Data From Bone Disease Study

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), along with partner Mereo BioPharma (MREO), announced new positive 14-month data from the phase II portion of the phase II/III Orbit study evaluating...

Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells

The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical over the use of HeLa cells taken without her consent in the 1950s. A Maryland federal court ruled against...

Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical

Latest Ratings for RARE
 DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsOverweight Feb 2022JP MorganUpgradesNeutralOverweight Feb 2022Morgan StanleyMaintainsOverweight
 View More Analyst...

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic...

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange...

Assenagon Asset Management S.A. Decreases Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Assenagon Asset Management S.A. lowered its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 32.4% in the fourth quarter, according to its most recent 13F filing...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...

Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ...

Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.

Volume	604,658.00
52-Wk High	$54.56
52-Wk Low	$31.52

RARE Ultragenyx Pharmaceutical Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals